ReviewCureus2025
Human Papillomavirus (HPV) Vaccine Utilization and Its Determinants Among Adolescents in the United Arab Emirates (UAE): A Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human papillomavirus (HPV) can cause a range of diseases, the most common being cervical cancer. Although vaccines have existed for decades and are highly effective at preventing the illness, vaccination coverage is low, specifically among adolescents. There has been some success in vaccination campaigns in the UAE among girls, but very low male adolescent vaccination rates. It is essential to identify vaccination patterns as well as predictors of uptake to improve public health outcomes. This narrative review included relevant studies published between 2005 and 2025 in the PubMed, Scopus, Google Scholar, ScienceDirect, and Embase databases. The MeSH terms used were "Human Papillomavirus vaccine," "HPV vaccine," "Human Papillomavirus," "HPV," "vaccine uptake," "immunization," and "United Arab Emirates." Following the introduction of HPV vaccination in adolescent girls in 2008, the UAE saw a dramatic expansion of coverage, with some areas exceeding 90%. However, recent trends show the number of adolescents initiating vaccination has declined while completion is rising. Male data are limited but demonstrate very low coverage. Determinants of the uptake of vaccines include awareness levels, religious and cultural attitudes, fear of side effects, and concerns about costs and availability of the vaccine. Doctor referral was an extremely powerful motivator for vaccination. The UAE is behind its immediate regional neighbors in the uptake of vaccines, but leads when compared to international standards. While the UAE has shown tremendous improvement in HPV vaccination, there remains some room for growth, especially in male adolescents. Expanding education, drifting from cultural resistance to vaccination, and increasing vaccine availability are measures that are crucial to optimizing vaccine distribution and reducing HPV-related illnesses in the years ahead.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.